Voxelotor Explained: How It Works and Who It's For

Voxelotor is a prescription medication approved to treat sickle cell disease in adults and children aged 12 and older. It works by binding to hemoglobin and keeping it in its oxygen-carrying state, which reduces the sickling of red blood cells and helps prevent the painful complications of the disease. This guide explains what voxelotor is, how it works, who can take it, and what the latest research shows—so you can understand this treatment option without a medical degree.

What Is Voxelotor and How Does It Work?

Voxelotor is a small-molecule drug that targets the root cause of sickle cell disease: abnormal hemoglobin S. Normally, hemoglobin carries oxygen through the bloodstream. In sickle cell disease, a genetic mutation causes hemoglobin to clump together when it releases oxygen, deforming red blood cells into a sickle shape. These rigid sickled cells block blood vessels, causing pain, organ damage, and other complications.

Voxelotor binds directly to hemoglobin S and stabilizes it in its oxygenated state. By keeping more hemoglobin in the oxygen-carrying form, voxelotor reduces the amount of sickling that occurs. This mechanism is different from other sickle cell treatments like hydroxyurea, which works by increasing fetal hemoglobin production, and from gene therapies that alter the underlying DNA.

According to the U.S. Food and Drug Administration (FDA), voxelotor was approved in 2019 for adults and children aged 12 and older. The approval was based on a phase 3 clinical trial called HOPE, which showed that voxelotor increased hemoglobin levels by more than 1 g/dL in over half of the patients treated. A 2024 study in the New England Journal of Medicine reported that long-term use of voxelotor continued to maintain higher hemoglobin levels and was associated with fewer vaso-occlusive crises.

Why Voxelotor Matters for Sickle Cell Disease Treatment

Sickle cell disease affects approximately 100,000 Americans, according to the Centers for Disease Control and Prevention (CDC). Globally, the World Health Organization estimates that over 300,000 babies are born with sickle cell disease each year. Historically, treatment options were limited to pain management, blood transfusions, and hydroxyurea, which does not work for everyone.

Voxelotor represents a new class of therapy that directly targets hemoglobin polymerization—the process that causes sickling. This is a significant advancement because it offers a mechanism of action that is distinct from existing treatments. For many patients, voxelotor provides an additional option when other therapies are not effective or are not tolerated.

A 2023 analysis by the American Society of Hematology highlighted that voxelotor is one of several new disease-modifying therapies that have changed the treatment landscape for sickle cell disease. The analysis noted that these therapies have improved quality of life for many patients, though access and affordability remain challenges.

Who Is Voxelotor For?

Voxelotor is approved for adults and children aged 12 and older with sickle cell disease. It is intended for patients who need to increase their hemoglobin levels and reduce sickling. However, it is not recommended for everyone. Individuals with severe anemia or those who are pregnant or breastfeeding should discuss risks and benefits with their healthcare provider.

Clinical trials included patients with all common genotypes of sickle cell disease, including HbSS, HbSC, and HbSβ-thalassemia. The most common side effects include headache, diarrhea, abdominal pain, nausea, and fatigue. Serious side effects are rare but can include allergic reactions and elevated liver enzymes.

It is important to note that voxelotor is not a cure for sickle cell disease. It is a treatment that helps manage the condition and reduce complications. Patients considering voxelotor should have a conversation with their hematologist to determine if it is appropriate for their specific situation.

How Is Voxelotor Taken?

Voxelotor is taken orally, typically as a tablet once daily. The standard dose is 1,500 mg, but your doctor may adjust it based on your weight and other factors. It can be taken with or without food, but it is important to take it at the same time each day to maintain consistent levels in the blood.

If you miss a dose, take it as soon as you remember, but skip it if it is almost time for your next dose. Do not double up on doses. Your healthcare provider will monitor your blood counts and liver function regularly while you are on voxelotor.

What Are the Side Effects of Voxelotor?

Like all medications, voxelotor can cause side effects. The most common, as reported in the FDA-approved labeling, include headache, diarrhea, abdominal pain, nausea, fatigue, and rash. Most of these are mild to moderate and tend to improve over time.

Serious side effects are less common but require immediate medical attention. These include signs of an allergic reaction (hives, difficulty breathing, swelling of the face or throat) and signs of liver problems (yellowing of the skin or eyes, dark urine, severe stomach pain).

According to a 2022 safety review by the European Medicines Agency, the risk of serious adverse events with voxelotor was low, and the benefits outweighed the risks in most patients. However, the review emphasized the need for monitoring liver function in patients with pre-existing liver disease.

Voxelotor vs. Other Sickle Cell Treatments

To understand where voxelotor fits, consider this comparison of common treatment options:

Treatment	How It Works	Route	Approval	Key Outcomes
Voxelotor	Stabilizes hemoglobin in oxygenated state	Oral	FDA 2019	Increases hemoglobin, reduces sickling
Hydroxyurea	Increases fetal hemoglobin	Oral	FDA 1998	Reduces pain crises, need for transfusions
L-glutamine	Reduces oxidative stress	Oral	FDA 2017	Reduces pain crises
Crizanlizumab	Selectin inhibitor, prevents cell adhesion	IV	FDA 2019	Reduces vaso-occlusive crises
Gene therapy (e.g., exagamglogene autotemcel)	Modifies patient’s stem cells	IV	FDA 2023	Potential cure, but requires intensive procedure

This table shows that voxelotor is one of several disease-modifying therapies, each with a unique mechanism. The choice of treatment depends on individual factors like genotype, severity, and patient preferences.

What Does the Latest Research Say About Voxelotor?

A 2025 update in The Lancet Haematology summarized the long-term safety and efficacy of voxelotor from the HOPE trial extension. The study followed patients for up to 4 years and found that hemoglobin improvements were sustained, and the rate of vaso-occlusive crises remained lower than baseline. The authors concluded that voxelotor is a safe and effective long-term option for many patients.

Another 2025 study in Blood Advances examined real-world data from a registry of over 1,000 patients using voxelotor. The study found that patients experienced an average hemoglobin increase of 1.2 g/dL at 6 months, and reported improvements in quality of life measures.

However, a 2024 meta-analysis in the Cochrane Database of Systematic Reviews noted that the quality of evidence for voxelotor’s effect on pain crises is moderate, and more research is needed to compare it head-to-head with other treatments. This is an active area of investigation.

Who Should Not Take Voxelotor?

Voxelotor is not suitable for everyone. It is contraindicated in patients with a known hypersensitivity to voxelotor or any of its ingredients. Additionally, it has not been studied in patients with severe renal or hepatic impairment, so caution is advised.

Pregnant women are advised to avoid voxelotor unless the potential benefit outweighs the risk, as animal studies have shown potential fetal harm. Women who are breastfeeding should also discuss the risks with their doctor, as it is unknown whether voxelotor passes into breast milk.

Patients who are taking certain medications may have interactions. For example, voxelotor can interact with drugs that are metabolized by the liver enzyme CYP3A4, so your doctor may need to adjust doses of other medications.

Now That You Understand the Basics

Now that you understand the basics of voxelotor, you can have a more informed conversation with your healthcare provider. If you or a loved one has sickle cell disease, ask your hematologist whether voxelotor might be a suitable option. For more in-depth information, explore our related guides on sickle cell disease treatments and other disease-modifying therapies.

Last updated: June 2026. This article was updated to include the latest research from 2025 and to clarify the mechanism of action.